Welcome!

Websphere Authors: Liz McMillan, Yeshim Deniz, Roger Strukhoff, Rajiv V. Joshi, Bruce W. McGaughy

News Feed Item

Tech Council of Maryland Names New Board Members

The Tech Council of Maryland (TCM), Maryland’s largest technology trade association for life science and technology, today announced that individuals from IBM, Sucampo Pharmaceuticals and the Universities at Shady Grove (USG) were named to the board of directors.

“The Tech Council of Maryland is very pleased to welcome our newest directors to the board,” said Phil Schiff, TCM’s CEO. “These individuals bring expertise in technology, life science and higher education that will enhance the depth and breadth of TCM’s leadership.”

The new board members include:

  • Stewart Edelstein, PhD, Executive Director, USG – Dr. Edelstein joined USG as executive director in 2002 and was named associate vice chancellor for Academic Affairs for the University System of Maryland in 2007. Under his leadership, USG expanded its number of participating universities, the breadth and depth of undergraduate and graduate degree programs, and grew student enrollment to more than 4,000 students. Further growth is planned with the construction of a new Biomedical Sciences and Engineering Education Facility, which will expand the degrees offered in the health and technology fields and result in doubling the number of students served by the campus.
  • Peter Greenleaf, CEO, Sucampo Pharmaceuticals – Greenleaf was named CEO of Sucampo Pharmaceuticals on March 3, 2014, and brings more than 20 years of experience in commercialization and drug development in the biopharmaceutical industry. Prior to Sucampo, Greenleaf was president, CEO and Board member of Histogenics, a regenerative medicine company. Previously, he served as president of MedImmune, the global biologics arm of AstraZeneca, where he was instrumental in driving the expansion of MedImmune's pipeline into over 120 clinical and pre-clinical programs and the commercialization of its marketed products. Greenleaf also served as president of MedImmune Ventures, a wholly owned venture capital fund within the AstraZeneca Group, where he led investment in emerging biopharmaceutical, medical device and diagnostic companies.
  • Chris Laidlaw, Enterprise Sales Director for Maryland and D.C., IBM Corporation –Laidlaw was named enterprise sales director for Maryland and the District of Columbia in January 2013. In this role, he is responsible for all of IBM’s sales activities across the breadth of IBM’s portfolio of products, solutions and services for all Maryland and D.C. clients. Previously, he served as client director for Industrial Sector Clients in IBM’s Mid-Atlantic Region. Laidlaw was responsible for leading a sales team dedicated to the success of all industrial sector accounts. Prior to that, he was IBM’s Global client director for CSC and led IBM’s growth in the computer services industry.

ABOUT THE TECH COUNCIL OF MARYLAND, INC.

The Tech Council of Maryland (TCM) is the largest technology trade group serving the advanced technology and biotechnology communities of Maryland. TCM’s mission is to advocate for the interests of the technology community, further the role of technology in the Maryland economy, and nurture an environment where technology companies can collaborate, grow and succeed. For more information, visit www.techcouncilmd.com.

More Stories By Business Wire

Copyright © 2009 Business Wire. All rights reserved. Republication or redistribution of Business Wire content is expressly prohibited without the prior written consent of Business Wire. Business Wire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.